ETON - Eton Pharmaceuticals Inc

ETON - Eton Pharmaceuticals Inc

https://www.etonpharma.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

GlobeNewswire • 3 weeks, 5 days ago • score: 0.25

DEER PARK, Ill., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Eton Pharmaceuticals, Inc ( "Eton" or the "Company" ) ( Nasdaq: ETON ) , an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive ...

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference - Eton Pharmaceuticals ( NASDAQ:ETON )

Benzinga • 3 weeks, 5 days ago • score: 0.21

DEER PARK, Ill., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Eton Pharmaceuticals, Inc ( "Eton" or the "Company" ) ETON, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team ...

Eton Pharmaceuticals, Inc. ( ETON ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.10

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -900.00% and +13.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

GlobeNewswire • 1 month, 2 weeks ago • score: 0.20

DEER PARK, Ill., July 28, 2025 ( GLOBE NEWSWIRE ) -- Eton Pharmaceuticals, Inc ( "Eton" or the "Company" ) ( Nasdaq: ETON ) , an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 ...

Eton Pharmaceuticals ( ETON ) Upgraded to Buy: Here's Why

Zacks Commentary • 3 months, 1 week ago • score: 0.33

Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.

52W High

$21.48

52W Low

$4.52

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.11

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

12.02

EV/EBITDA (<8 favorable)

259.85

EV/Revenue (<3 favorable)

8.24

P/S (TTM) (<3 favorable)

8.14

P/B (<3 favorable)

19.78

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.39%

Institutions (25–75% balanced)

62.48%

Shares Outstanding

26,817,500

Float

17,961,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

58,181,000

Gross Profit (TTM)

36,912,000

EPS (TTM)

-0.15

Profit Margin (>10% good)

-0.07%

Operating Margin (TTM) (higher better)

-0.01%

ROE (TTM) (>15% strong)

-0.22%

EPS YoY (Quarterly) (>10% good)

-0.13

Revenue YoY (Quarterly) (>8% good)

1.09

Momentum

Bearish momentum

Value

0.5196

Previous

0.5442

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025